company background image
MOC logo

Molecure WSE:MOC Stock Report

Last Price

zł17.12

Market Cap

zł288.2m

7D

-3.3%

1Y

-19.8%

Updated

26 Mar, 2024

Data

Company Financials +

MOC Stock Overview

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.

MOC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Molecure S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Molecure
Historical stock prices
Current Share Pricezł17.12
52 Week Highzł26.25
52 Week Lowzł15.64
Beta2.21
1 Month Change-13.88%
3 Month Change-8.74%
1 Year Change-19.81%
3 Year Change-68.18%
5 Year Change-12.65%
Change since IPO-40.97%

Recent News & Updates

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Recent updates

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Shareholder Returns

MOCPL PharmaceuticalsPL Market
7D-3.3%-2.5%2.1%
1Y-19.8%-2.9%35.7%

Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned -0.5% over the past year.

Return vs Market: MOC underperformed the Polish Market which returned 34.3% over the past year.

Price Volatility

Is MOC's price volatile compared to industry and market?
MOC volatility
MOC Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement5.0%
10% most volatile stocks in PL Market9.6%
10% least volatile stocks in PL Market3.3%

Stable Share Price: MOC has not had significant price volatility in the past 3 months.

Volatility Over Time: MOC's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012109Marcin Szumowskihttps://molecure.com

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.

Molecure S.A. Fundamentals Summary

How do Molecure's earnings and revenue compare to its market cap?
MOC fundamental statistics
Market capzł288.23m
Earnings (TTM)-zł17.41m
Revenue (TTM)zł1.38m

209.5x

P/S Ratio

-16.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MOC income statement (TTM)
Revenuezł1.38m
Cost of Revenuezł1.80m
Gross Profit-zł424.51k
Other Expenseszł16.99m
Earnings-zł17.41m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 29, 2024

Earnings per share (EPS)-1.03
Gross Margin-30.86%
Net Profit Margin-1,265.69%
Debt/Equity Ratio0%

How did MOC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.